PAHC vs. SRPT, MRUS, ACLX, ACAD, SWTX, RARE, PTGX, SRRK, ALVO, and MTSR
Should you be buying Phibro Animal Health stock or one of its competitors? The main competitors of Phibro Animal Health include Sarepta Therapeutics (SRPT), Merus (MRUS), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Protagonist Therapeutics (PTGX), Scholar Rock (SRRK), Alvotech (ALVO), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry.
Phibro Animal Health vs. Its Competitors
Phibro Animal Health (NASDAQ:PAHC) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation.
Sarepta Therapeutics has a net margin of 7.43% compared to Phibro Animal Health's net margin of 1.75%. Phibro Animal Health's return on equity of 25.35% beat Sarepta Therapeutics' return on equity.
Phibro Animal Health has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.
In the previous week, Sarepta Therapeutics had 8 more articles in the media than Phibro Animal Health. MarketBeat recorded 12 mentions for Sarepta Therapeutics and 4 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.44 beat Sarepta Therapeutics' score of 0.71 indicating that Phibro Animal Health is being referred to more favorably in the media.
Phibro Animal Health has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.
Sarepta Therapeutics received 1166 more outperform votes than Phibro Animal Health when rated by MarketBeat users. Likewise, 75.01% of users gave Sarepta Therapeutics an outperform vote while only 59.81% of users gave Phibro Animal Health an outperform vote.
99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by insiders. Comparatively, 7.7% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Phibro Animal Health currently has a consensus price target of $20.00, indicating a potential downside of 16.42%. Sarepta Therapeutics has a consensus price target of $122.61, indicating a potential upside of 238.89%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sarepta Therapeutics is more favorable than Phibro Animal Health.
Summary
Sarepta Therapeutics beats Phibro Animal Health on 10 of the 19 factors compared between the two stocks.
Get Phibro Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PAHC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PAHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phibro Animal Health Competitors List
Related Companies and Tools
This page (NASDAQ:PAHC) was last updated on 6/14/2025 by MarketBeat.com Staff
Buy PAHC Stock Free PAHC Stock Alerts